Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

modified Rankin Scale

  • Home
  • modified Rankin Scale
Avoiding Intensive Systolic Blood Pressure Lowering After Successful Thrombectomy May Improve 1-Year Stroke Recovery: The OPTIMAL-BP Extension
Posted inCritical Care Neurology news

Avoiding Intensive Systolic Blood Pressure Lowering After Successful Thrombectomy May Improve 1-Year Stroke Recovery: The OPTIMAL-BP Extension

Posted by MedXY By MedXY 05/31/2026
In OPTIMAL-BP 1-year follow-up, targeting systolic BP <140 mm Hg after successful thrombectomy was associated with worse long-term functional recovery than conventional BP management.
Read More
DISTAL at 12 Months: No Functional or Survival Advantage for Endovascular Therapy in Mild-to-Moderate Medium or Distal Vessel Occlusion Stroke
Posted inEmergency Medicine Neurology news

DISTAL at 12 Months: No Functional or Survival Advantage for Endovascular Therapy in Mild-to-Moderate Medium or Distal Vessel Occlusion Stroke

Posted by MedXY By MedXY 05/13/2026
The DISTAL trial found no 12-month disability or survival benefit from adding endovascular treatment to best medical therapy in mild-to-moderate medium or distal vessel occlusion stroke.
Read More
  • Housing Instability Linked to Cost-Related Medication Nonadherence and Financial Hardship in Adults with Uncontrolled Diabetes
  • Once-weekly IcoSema versus Daily Insulin Glargine U100 in Type 2 Diabetes: Evidence from the COMBINE 4 Phase 3b Trial and Related Advances
  • Personalized Risk Modeling of Interatrial Shunt Therapy in Heart Failure: Insights from the RELIEVE-HF Trial
  • Long-Term Benefits of Surgical Unroofing in Angina Patients with Myocardial Bridge and Non-Obstructive Coronary Arteries
  • Acute Effects of Cannabis Inhalation on Cardiac Ectopy, Physical Activity, Sleep, and Glucose: A Synthesis of Clinical Evidence and Mechanistic Insights
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in